Literature DB >> 3948371

Vulnerability to ventricular arrhythmia: assessment by mapping of body surface potential.

M J Gardner, T J Montague, C S Armstrong, B M Horacek, E R Smith.   

Abstract

It is now well established that the vulnerability of the ventricular myocardium to repetitive dysrhythm increases in the presence of greater than normal disparity local recovery times. Local recovery is reflected in the electrocardiographic waveform as an area of the ventricular deflection (QRST time integral), and thus disparate ventricular recovery may be manifested in the body surface distribution of this quality. To assess this possibility, we obtained simultaneous 120-lead electrocardiograms from both the anterior and posterior torso in 140 subjects (ages 8 to 75) grouped as follows: group A, 97 normal subjects; group B, 16 patients resuscitated from ventricular fibrillation or sustained ventricular tachycardia; and group C, 27 patients 6 to 12 months after myocardial infarction but without clinically significant arrhythmia. In each subject, the QRST integral was evaluated for each lead and isointegral contour maps were plotted. A score was assigned to each map, based on the number of extrema; each maximum or minimum scored one point, with the exception of simultaneously occurring anterior and posterior minima on the right shoulder (frequently occurring in normal subjects), which scored together only one point. All but one group A subject had dipolar QRST integral maps (mean +/- SD score 2.11 +/- 0.2). Conversely, 10 of 16 (62.5%) group B patients had scores of 3 or more (mean 3.16 +/- 1.08; p less than .01 vs group A). Group C patients had intermediate values, with eight of 27 (29.6%) scoring 3 or more (mean 2.46 +/- 83); this was less than in group B (p less than .01), but more (p less than .05) than in group A.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 3948371     DOI: 10.1161/01.cir.73.4.684

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

Review 1.  Body surface potential mapping: historical background, present possibilities, diagnostic challenges.

Authors:  Mihály Medvegy; Gábor Duray; Arnold Pintér; István Préda
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-04       Impact factor: 1.468

2.  Classification of pathologies by reduced sequential potential maps.

Authors:  D Adam; S Gilat
Journal:  Med Biol Eng Comput       Date:  1992-01       Impact factor: 2.602

3.  Ventricular arrhythmia is predicted by sum absolute QRST integralbut not by QRS width.

Authors:  Larisa G Tereshchenko; Alan Cheng; Barry J Fetics; Joseph E Marine; David D Spragg; Sunil Sinha; Hugh Calkins; Gordon F Tomaselli; Ronald D Berger
Journal:  J Electrocardiol       Date:  2010-09-15       Impact factor: 1.438

4.  Body Surface Potential Mapping: Contemporary Applications and Future Perspectives.

Authors:  Jake Bergquist; Lindsay Rupp; Brian Zenger; James Brundage; Anna Busatto; Rob S MacLeod
Journal:  Hearts (Basel)       Date:  2021-11-05

5.  [Analysis of QRST integral and QT dispersion by body surface potential mapping in patients with malignant ventricular arrhythmias].

Authors:  C Stellbrink; E Stegemann; R Killmann; K Mischke; H Schütt; P Hanrath
Journal:  Herzschrittmacherther Elektrophysiol       Date:  1997-06

6.  A new electrocardiogram marker to identify patients at low risk for ventricular tachyarrhythmias: sum magnitude of the absolute QRST integral.

Authors:  Larisa G Tereshchenko; Alan Cheng; Barry J Fetics; Barbara Butcher; Joseph E Marine; David D Spragg; Sunil Sinha; Darshan Dalal; Hugh Calkins; Gordon F Tomaselli; Ronald D Berger
Journal:  J Electrocardiol       Date:  2010-11-20       Impact factor: 1.438

7.  Risk assessment of ventricular arrhythmia using new parameters based on high resolution body surface potential mapping.

Authors:  Malgorzata Fereniec; Gunter Stix; Michal Kania; Tomasz Mroczka; Dariusz Janusek; Roman Maniewski
Journal:  Med Sci Monit       Date:  2011-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.